Paul Deaton, MD
Critical Care Medicine · Memphis, TNNPI 1235110313
Payments from drug & device makers
Across 558 payments — averaging $42.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals, Ltd$11K
- Actelion Pharmaceuticals US, Inc.$4K
- GSK$2K
- AstraZeneca$2K
- United Therapeutics Corporation$933
- Sanofi$546
- plus $4K from 32 others
What the payments were for
- Food & beverage$9,68299%
- Education$581%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals, Ltd | 5 | $10,800 |
| Actelion Pharmaceuticals US, Inc. | 39 | $3,723 |
| GSK | 141 | $1,780 |
| AstraZeneca | 73 | $1,545 |
| United Therapeutics Corporation | 43 | $933 |
| Sanofi | 25 | $546 |
| Insmed, Inc. | 27 | $517 |
| Boehringer Ingelheim | 32 | $457 |
| Genentech USA, Inc. | 18 | $410 |
| Regeneron Healthcare Solutions, Inc. | 15 | $352 |
| Harmony Biosciences LLC | 12 | $267 |
| Merck | 13 | $226 |
| Grifols USA, LLC | 14 | $222 |
| Inari Medical, Inc. | 1 | $208 |
| Mylan Specialty L.p. | 15 | $196 |
| Amgen | 8 | $129 |
| Verona Pharma, Inc. | 8 | $129 |
| Bayer | 6 | $87 |
| AbbVie(2 entities) | 6 | $82 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $82 |
| Novartis | 5 | $81 |
| Mallinckrodt Hospital Products Inc. | 5 | $80 |
| Lilly USA, LLC | 5 | $78 |
| La Jolla Pharmaceutical Company | 5 | $78 |
| ANI Pharmaceuticals, Inc. | 3 | $66 |
| Pfizer | 4 | $64 |
| Sunovion Pharmaceuticals Inc. | 5 | $63 |
| Baxter Healthcare | 3 | $61 |
| Mallinckrodt Enterprises LLC | 3 | $49 |
| Tetraphase Pharmaceuticals, Inc. | 2 | $34 |
| Vapotherm Inc | 3 | $33 |
| Viatris Specialty LLC | 2 | $31 |
| Gilead | 2 | $27 |
| CSL Behring | 1 | $22 |
| Caris MPI, Inc. | 1 | $19 |
| Philips North America LLC | 1 | $18 |
| Inogen, Inc. | 1 | $15 |
| Advanced Respiratory, Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$474
- FASENRA$474
- UPTRAVI$261
- OPSUMIT$261
- TEZSPIRE$239
- AIRSUPRA$239
- SYMBICORT$235
- FlowTriever$208
- ClotTriever$208
How this compares
$23,521 in reported general payments places this provider in the 90th percentile of 141 critical care medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UptraviSelexipag | 35 | $827,438 |
| OfevNintedanib Esylate | 47 | $612,776 |
| OpsumitMacitentan | 28 | $356,143 |
| ArikayceAmikacin Liposomal/Neb.Accessr | 14 | $203,817 |
| TracleerBosentan | 13 | $163,579 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 170 | $147,673 |
| Ambrisentan | 16 | $105,538 |
| Bosentan | 12 | $67,992 |
| Spiriva RespimatTiotropium Bromide | 78 | $55,908 |
| Tadalafil | 24 | $54,461 |
| Breo ElliptaFluticasone/Vilanterol | 103 | $53,671 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 48 | $38,126 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 48 | $28,993 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 20 | $13,467 |
| Pirfenidone | 12 | $11,700 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit, Tracleer, Bosentan | $3,723 | $1,415,15288 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $457 | $682,151145 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $1,780 | $244,892354 claims |
| Insmed, Inc.Arikayce | $517 | $203,81714 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $1,545 | $52,20686 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 141 critical care medicine providers in Tennessee.
Other critical care medicine in Memphis
- Anthony MattoxMemphis$33K
- Nathan WildsMemphis$19K
- Robert AguillardMemphis$11K
- Kimberly MarshMemphis$11K
- Garrettson EllisMemphis$9K
- Roy FoxMemphis$9K
- Matthew MabieMemphis$7K
- Steven WoodsMemphis$6K
- William RichardsMemphis$6K
- Michael MundayMemphis$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.